Monte Rosa Therapeutics Net Income
| GLUE Stock | USD 18.50 0.46 2.43% |
As of the 13th of February 2026, Monte Rosa secures the Risk Adjusted Performance of 0.1026, mean deviation of 4.21, and Downside Deviation of 4.2. Monte Rosa Therapeutics technical analysis lets you operate historical price patterns with an objective to determine a pattern that forecasts the direction of the firm's future prices. Please verify Monte Rosa Therapeutics jensen alpha, as well as the relationship between the potential upside and skewness to decide if Monte Rosa Therapeutics is priced some-what accurately, providing market reflects its recent price of 18.5 per share. Given that Monte Rosa Therapeutics has jensen alpha of 0.8298, we recommend you to check Monte Rosa's last-minute market performance to make sure the company can sustain itself at a future point.
Monte Rosa Total Revenue |
|
Gross Profit | Profit Margin | Market Capitalization | Enterprise Value Revenue 6.0289 | Revenue |
| Last Reported | Projected for Next Year | ||
| Net Loss | -65.4 M | -68.7 M | |
| Net Loss | -97.7 M | -102.5 M | |
| Net Loss | -65.4 M | -68.7 M | |
| Net Loss | (1.13) | (1.19) | |
| Net Income Per E B T | 0.93 | 0.82 |
Monte | Net Income | Build AI portfolio with Monte Stock |
Analyzing Monte Rosa's Net Income over time reveals critical patterns in financial health and operational efficiency. This metric helps investors evaluate trends, identify inflection points, and make informed decisions based on historical performance. Understanding how Net Income has evolved provides context for assessing Monte Rosa's current valuation and future prospects.
Latest Monte Rosa's Net Income Growth Pattern
Below is the plot of the Net Income of Monte Rosa Therapeutics over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Monte Rosa Therapeutics financial statement analysis. It represents the amount of money remaining after all of Monte Rosa Therapeutics operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Monte Rosa's Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Monte Rosa's overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (72.7 M) | 10 Years Trend |
|
Net Income |
| Timeline |
Monte Net Income Regression Statistics
| Arithmetic Mean | (37,687,735) | |
| Coefficient Of Variation | (110.27) | |
| Mean Deviation | 35,119,540 | |
| Median | (8,017,000) | |
| Standard Deviation | 41,557,567 | |
| Sample Variance | 1727T | |
| Range | 127.3M | |
| R-Value | (0.76) | |
| Mean Square Error | 764.9T | |
| R-Squared | 0.58 | |
| Significance | 0.0003 | |
| Slope | (6,293,194) | |
| Total Sum of Squares | 27632.5T |
Monte Net Income History
Other Fundumenentals of Monte Rosa Therapeutics
| Net Income From Continuing Ops | ||
| Net Income Applicable To Common Shares | ||
| Net Income Per Share | ||
| Net Income Per E B T |
Monte Rosa Net Income component correlations
Monte Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Monte Rosa is extremely important. It helps to project a fair market value of Monte Stock properly, considering its historical fundamentals such as Net Income. Since Monte Rosa's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Monte Rosa's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Monte Rosa's interrelated accounts and indicators.
Click cells to compare fundamentals
Will Biotechnology sector continue expanding? Could Monte diversify its offerings? Factors like these will boost the valuation of Monte Rosa. Market participants price Monte higher when confident in its future expansion prospects. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Monte Rosa data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share 0.32 | Revenue Per Share | Quarterly Revenue Growth 0.385 | Return On Assets | Return On Equity |
Monte Rosa Therapeutics's market price often diverges from its book value, the accounting figure shown on Monte's balance sheet. Smart investors calculate Monte Rosa's intrinsic value - its true economic worth - which may differ significantly from both market price and book value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Since Monte Rosa's trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
Please note, there is a significant difference between Monte Rosa's value and its price as these two are different measures arrived at by different means. Investors typically determine if Monte Rosa is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Monte Rosa's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Monte Rosa 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Monte Rosa's stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Monte Rosa.
| 11/15/2025 |
| 02/13/2026 |
If you would invest 0.00 in Monte Rosa on November 15, 2025 and sell it all today you would earn a total of 0.00 from holding Monte Rosa Therapeutics or generate 0.0% return on investment in Monte Rosa over 90 days. Monte Rosa is related to or competes with Day One, Arvinas, Replimune, Theravance Biopharma, ArriVent BioPharma, Geron, and Vir Biotechnology. Monte Rosa Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel small molecule precision... More
Monte Rosa Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Monte Rosa's stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Monte Rosa Therapeutics upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 4.2 | |||
| Information Ratio | 0.1044 | |||
| Maximum Drawdown | 53.94 | |||
| Value At Risk | (6.69) | |||
| Potential Upside | 11.18 |
Monte Rosa Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Monte Rosa's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Monte Rosa's standard deviation. In reality, there are many statistical measures that can use Monte Rosa historical prices to predict the future Monte Rosa's volatility.| Risk Adjusted Performance | 0.1026 | |||
| Jensen Alpha | 0.8298 | |||
| Total Risk Alpha | 0.1982 | |||
| Sortino Ratio | 0.183 | |||
| Treynor Ratio | 6.52 |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Monte Rosa's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Monte Rosa February 13, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.1026 | |||
| Market Risk Adjusted Performance | 6.53 | |||
| Mean Deviation | 4.21 | |||
| Semi Deviation | 3.73 | |||
| Downside Deviation | 4.2 | |||
| Coefficient Of Variation | 866.45 | |||
| Standard Deviation | 7.36 | |||
| Variance | 54.11 | |||
| Information Ratio | 0.1044 | |||
| Jensen Alpha | 0.8298 | |||
| Total Risk Alpha | 0.1982 | |||
| Sortino Ratio | 0.183 | |||
| Treynor Ratio | 6.52 | |||
| Maximum Drawdown | 53.94 | |||
| Value At Risk | (6.69) | |||
| Potential Upside | 11.18 | |||
| Downside Variance | 17.62 | |||
| Semi Variance | 13.9 | |||
| Expected Short fall | (4.96) | |||
| Skewness | 3.64 | |||
| Kurtosis | 20.33 |
Monte Rosa Therapeutics Backtested Returns
Monte Rosa appears to be somewhat reliable, given 3 months investment horizon. Monte Rosa Therapeutics has Sharpe Ratio of 0.1, which conveys that the firm had a 0.1 % return per unit of risk over the last 3 months. By analyzing Monte Rosa's technical indicators, you can evaluate if the expected return of 0.75% is justified by implied risk. Please exercise Monte Rosa's Downside Deviation of 4.2, risk adjusted performance of 0.1026, and Mean Deviation of 4.21 to check out if our risk estimates are consistent with your expectations. On a scale of 0 to 100, Monte Rosa holds a performance score of 7. The company secures a Beta (Market Risk) of 0.13, which conveys not very significant fluctuations relative to the market. As returns on the market increase, Monte Rosa's returns are expected to increase less than the market. However, during the bear market, the loss of holding Monte Rosa is expected to be smaller as well. Please check Monte Rosa's sortino ratio, skewness, period momentum indicator, as well as the relationship between the potential upside and rate of daily change , to make a quick decision on whether Monte Rosa's current price movements will revert.
Auto-correlation | 0.65 |
Good predictability
Monte Rosa Therapeutics has good predictability. Overlapping area represents the amount of predictability between Monte Rosa time series from 15th of November 2025 to 30th of December 2025 and 30th of December 2025 to 13th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Monte Rosa Therapeutics price movement. The serial correlation of 0.65 indicates that roughly 65.0% of current Monte Rosa price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.65 | |
| Spearman Rank Test | 0.36 | |
| Residual Average | 0.0 | |
| Price Variance | 9.49 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Monte Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Monte Rosa Therapeutics reported net income of (72.7 Million). This is 121.3% lower than that of the Biotechnology sector and 203.79% lower than that of the Health Care industry. The net income for all United States stocks is 112.73% higher than that of the company.
Monte Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Monte Rosa's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Monte Rosa could also be used in its relative valuation, which is a method of valuing Monte Rosa by comparing valuation metrics of similar companies.Monte Rosa is currently under evaluation in net income category among its peers.
Monte Rosa Current Valuation Drivers
We derive many important indicators used in calculating different scores of Monte Rosa from analyzing Monte Rosa's financial statements. These drivers represent accounts that assess Monte Rosa's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Monte Rosa's important valuation drivers and their relationship over time.
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 (projected) | ||
| Market Cap | 950.3M | 359.4M | 290.4M | 512.9M | 589.9M | 729.1M | |
| Enterprise Value | 604.2M | 351.5M | 208.3M | 331.4M | 381.1M | 619.7M |
Monte Rosa ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Monte Rosa's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Monte Rosa's managers, analysts, and investors.Environmental | Governance | Social |
Monte Rosa Institutional Holders
Institutional Holdings refers to the ownership stake in Monte Rosa that is held by large financial organizations, pension funds or endowments. Institutions may hold large blocks of Monte Rosa's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Monte Rosa's value.| Shares | Alphabet Inc | 2025-06-30 | 1.5 M | Aqr Capital Management Llc | 2025-06-30 | 1.3 M | Geode Capital Management, Llc | 2025-06-30 | 1.1 M | State Street Corp | 2025-06-30 | 831.8 K | Northern Trust Corp | 2025-06-30 | 761.4 K | Parkwood Llc | 2025-06-30 | 708 K | Renaissance Technologies Corp | 2025-06-30 | 615.1 K | Morgan Stanley - Brokerage Accounts | 2025-06-30 | 570.5 K | Royal Bank Of Canada | 2025-06-30 | 469.8 K | Nea Management Company, Llc | 2025-06-30 | 7.7 M | T. Rowe Price Associates, Inc. | 2025-06-30 | 6.3 M |
Monte Fundamentals
| Return On Equity | 0.0928 | ||||
| Return On Asset | 0.0137 | ||||
| Profit Margin | 0.12 % | ||||
| Operating Margin | (2.58) % | ||||
| Current Valuation | 1.09 B | ||||
| Shares Outstanding | 76.24 M | ||||
| Shares Owned By Insiders | 0.81 % | ||||
| Shares Owned By Institutions | 94.33 % | ||||
| Number Of Shares Shorted | 7.66 M | ||||
| Price To Earning | 1.91 X | ||||
| Price To Book | 5.88 X | ||||
| Price To Sales | 7.96 X | ||||
| Revenue | 75.62 M | ||||
| Gross Profit | 50.97 M | ||||
| EBITDA | (72.99 M) | ||||
| Net Income | (72.7 M) | ||||
| Cash And Equivalents | 294.14 M | ||||
| Cash Per Share | 6.32 X | ||||
| Total Debt | 42.72 M | ||||
| Debt To Equity | 0.16 % | ||||
| Current Ratio | 20.11 X | ||||
| Book Value Per Share | 3.98 X | ||||
| Cash Flow From Operations | 42 M | ||||
| Short Ratio | 3.05 X | ||||
| Earnings Per Share | 0.32 X | ||||
| Target Price | 33.8 | ||||
| Number Of Employees | 147 | ||||
| Beta | 1.62 | ||||
| Market Capitalization | 1.45 B | ||||
| Total Asset | 438.73 M | ||||
| Retained Earnings | (438.59 M) | ||||
| Working Capital | 220.49 M | ||||
| Net Asset | 438.73 M |
About Monte Rosa Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Monte Rosa Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Monte Rosa using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Monte Rosa Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Monte Rosa Therapeutics is a strong investment it is important to analyze Monte Rosa's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Monte Rosa's future performance. For an informed investment choice regarding Monte Stock, refer to the following important reports:Check out You can also try the AI Portfolio Prophet module to use AI to generate optimal portfolios and find profitable investment opportunities.
Will Biotechnology sector continue expanding? Could Monte diversify its offerings? Factors like these will boost the valuation of Monte Rosa. Market participants price Monte higher when confident in its future expansion prospects. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Monte Rosa data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share 0.32 | Revenue Per Share | Quarterly Revenue Growth 0.385 | Return On Assets | Return On Equity |
Monte Rosa Therapeutics's market price often diverges from its book value, the accounting figure shown on Monte's balance sheet. Smart investors calculate Monte Rosa's intrinsic value - its true economic worth - which may differ significantly from both market price and book value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Since Monte Rosa's trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
Please note, there is a significant difference between Monte Rosa's value and its price as these two are different measures arrived at by different means. Investors typically determine if Monte Rosa is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Monte Rosa's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.